7 completed, 2 active not recruiting, 1 no longer available, 1 terminated. 8 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Active not recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Capricor Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Deramiocel (CAP-1002), Placebo - Muscular Dystrophies, Muscular Dystrophy, Duchenne | Phase 3 | Active not recruiting | Capricor Inc. | 106 | 2022-06-22 | 2026-08-28 |
| Intravenous Infusion of CAP-1002 in Patients With COVID-19 CAP-1002, Placebo - Covid19 | Phase 2 | Completed | Capricor Inc. | 55 | 2020-11-15 | 2025-02-20 |
| Open-label Extension of the HOPE-2 Trial Deramiocel (CAP-1002) - Duchenne Muscular Dystrophy | Phase 2 | Active not recruiting | Capricor Inc. | 13 | 2020-08-05 | 2026-09-22 |
| Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families Duchenne Muscular Dystrophy, Burden, Dependency | Completed | Jett Foundation, Inc. | 60 | 2018-09-20 | 2019-04-01 | |
| Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) Allogeneic Cardiosphere-Derived Cells (CAP-1002) - Duchenne Muscular Dystrophy | Phase 2 | Completed | Capricor Inc. | 8 | 2018-06-21 | 2024-04-24 |
| A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy CAP-1002, Placebo - Muscular Dystrophies, Muscular Dystrophy, Duchenne | Phase 2 | Completed | Capricor Inc. | 20 | 2018-04-04 | 2025-05-28 |
| HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) Allogeneic Cardiosphere-Derived Cells (CAP-1002) - Duchenne Muscular Dystrophy, Cardiomyopathy | Phase 2 | Completed | Capricor Inc. | 25 | 2016-01-07 | 2025-01-09 |
| Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment Cenderitide, Placebo - Heart Failure, Renal Insufficiency | Phase 1 / Phase 2 | Completed | Capricor Inc. | 8 | 2015-12-01 | 2020-02-11 |
| Safety Study of Cenderitide in Stable Chronic Heart Failure Cenderitide - Heart Failure | Phase 2 | Completed | Capricor Inc. | 14 | 2015-01-01 | 2020-02-11 |
| Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC) Allogeneic Cardiosphere-Derived Cells (CDCs) - Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy | Phase 1 | Unknown | Capricor Inc. | 42 | 2014-11-01 | 2016-06-21 |
| Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration CAP-1002 Allogeneic Cardiosphere-Derived Cells, Placebo - Myocardial Infarction | Phase 1 / Phase 2 | Terminated | Capricor Inc. | 135 | 2012-11-13 | 2024-04-09 |
| CAP-1002 in Severe COVID-19 Disease CAP-1002 Allogeneic Cardiosphere-Derived Cells - COVID-19 | No longer available | Capricor Inc. | 2020-12-01 |
Muscular Dystrophy, Duchenne (6) · Heart Failure (4) · Cardiomyopathies (3) · Muscular Dystrophies (3) · COVID-19 (2) · Genetic Diseases, Inborn (2) · Genetic Diseases, X-Linked (2) · Muscular Diseases (2) · Muscular Disorders, Atrophic (2) · Nervous System Diseases (2) · Neuromuscular Diseases (2) · Cardiomyopathy, Dilated (1) · Cardiovascular Diseases (1) · Heart Diseases (1) · Myocardial Infarction (1)
cenderitide (2) · chenodeoxycholate sulfate conjugate (2)
United States (12)
Mark Awadalla (4) · Craig McDonald, MD (3) · Deborah Ascheim, MD (2) · Christine McSherry, R.N. (1) · Frank Litvack, MD (1) · Joel Neutel, MD (1) · Raj Makkar, MD (1) · Tim Albertson, MD (1)
PMID 32749459, PMID 34233913, PMID 35279258, PMID 42526472
R44HL095203 (1), RC3HL103356-01 (1)